Journal of Clinical and Experimental Ophthalmology
Open Access

Abstract

Five-year treatment outcomes of macular edema secondary to CRVO in routine clinical practice: The Fight Retinal Blindness! Registry

Katrin Rudolph

Purpose: To report 5-year outcomes in a cohort of patients who received anti-VEGF therapy for macular edema secondary to Central Retinal Vein Occlusion (CRVO) in routine clinical practice.

Design: In this retrospective observational study, anonymized data from various countries contributing to the CRVO module of the Fight Retinal Blindness! Registry was analyzed. Methods: A total of 593 treatment-naïve eyes that commenced anti-VEGF treatment between January 1, 2010 and 2019 were analyzed. Outcome measures included mean changes in Visual Acuity (VA) and Central Subfield Thickness (CST).

Results: In the entire cohort (593), the mean VA changed by +8 letters and the mean CST by 298 μm. The entire cohort includes eyes with completed 5-year follow-up and non-completers who dropped out before the end of the observation period. Eyes that completed the 5-year follow-up (202/593, 34%) had a mean VA and CST change of +11 letters and -320 μm with a median of 25.5 injections at 39.5 visits. Non-completers with a final VA of >70 letters (95/593; 16%) experienced a change in mean VA of +23 letters. The average follow-up duration was 731 days, with a median of 8 injections. In non-completers with a final VA between 35 and 70 letters (163/593; 27%), the mean VA increased by 12 letters. Over an average follow-up period of 774 days, 11 injections were received. In non-completers with a final VA of <35 letters (133/593; 22%), the mean VA declined by 12 letters. Over a mean follow-up period of 752 days, an average of 7 injections was administered.

Conclusion: Patients with macular edema secondary to CRVO who continue treatment can achieve meaningful improvements in vision over an extended period. Patients with initially poor vision tend to have large improvements but the worst outcomes. In contrast, eyes with very good initial VA can achieve excellent functional results and may even stop treatment at some point with adequate therapy.

Published Date: 2025-11-03; Received Date: 2025-09-30